Compartir
Screening for Oral Cancer: A Targeted Evidence Update for the U.S. Preventive Services Task Force: Evidence Synthesis Number 102 (en Inglés)
U. S. Department of Heal Human Services
(Autor)
·
Agency for Healthcare Resea And Quality
(Autor)
·
Createspace Independent Publishing Platform
· Tapa Blanda
Screening for Oral Cancer: A Targeted Evidence Update for the U.S. Preventive Services Task Force: Evidence Synthesis Number 102 (en Inglés) - And Quality, Agency for Healthcare Resea ; Human Services, U. S. Department of Heal
$ 23.390
$ 38.990
Ahorras: $ 15.600
Elige la lista en la que quieres agregar tu producto o crea una nueva lista
✓ Producto agregado correctamente a la lista de deseos.
Ir a Mis Listas
Origen: Estados Unidos
(Costos de importación incluídos en el precio)
Se enviará desde nuestra bodega entre el
Lunes 12 de Agosto y el
Lunes 19 de Agosto.
Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.
Reseña del libro "Screening for Oral Cancer: A Targeted Evidence Update for the U.S. Preventive Services Task Force: Evidence Synthesis Number 102 (en Inglés)"
In 2004, the U.S Preventive Services Task Force (USPSTF) found insufficient evidence in its review to recommend for or against screening for oral cancer. In this review, we are updating the evidence search and analysis to allow this recommendation to be reconsidered. Oral cancer includes cancers of the lip, oral cavity, and pharynx. Ninety percent of cancers of the oral cavity are squamous cell carcinomas (SCCs) arising from the mucosal lining. The other 10 percent of oral cancers are malignant melanomas, salivary gland tumors, sarcomas of the soft tissues or jaw bones, nonHodgkin's lymphomas, or metastases from extra-oral primary tumors. The USPSTF requested this targeted update to focus on the evidence gap in the conceptual framework about screening for oral cancer (i.e., any test or combination of tests used to detect PMDs or cancer of the lip, oral cavity, or pharynx). The two key questions are: Key Question 1 (KQ 1): Does screening for oral cancer reduce morbidity or mortality? Key Question 2 (KQ 2): What are the performance characteristics of the screening oral examination as a means of identifying oral cancer or PMDs for oral cancer?
